HALO vs. KYMR: Halozyme Therapeutics vs. Kymera Therapeutics Stock Comparison
How do Halozyme Therapeutics (HALO) and Kymera Therapeutics (KYMR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Halozyme Therapeutics (HALO) and Kymera Therapeutics (KYMR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Halozyme Therapeutics (HALO) has more than two decades of public-market history since March 16, 2004, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.
| Profile Item | HALO | KYMR |
|---|---|---|
| Name | Halozyme Therapeutics Inc. | Kymera Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 11.81 billion USD | 11.25 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | March 16, 2004 | August 21, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | HALO | KYMR |
|---|---|---|
| Total Return (1Y) | 50.94% | 131.52% |
| Total Return (3Y, Annualized) | 41.08% | 111.65% |
| Total Return (5Y, Annualized) | 21.68% | 15.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | HALO | KYMR |
|---|---|---|
| Volatility (1Y, Annualized) | 41.19% | 62.83% |
| Beta (5Y) | 0.96 | 2.00 |
| Max Drawdown (5Y) | -49.06% | -83.27% |
| Avg. Volume (3M) | 2.29M | 833.05K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | HALO | KYMR |
|---|---|---|
| Sharpe Ratio (1Y) | 1.13 | 2.03 |
| Sortino Ratio (1Y) | 1.78 | 4.16 |
Profitability
ROE (TTM)
Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Halozyme Therapeutics (HALO) reports 216.38%, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-27.29%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- KYMR
- -27.29%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- KYMR
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Halozyme Therapeutics (HALO) reports 59.84%, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-396.04%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- KYMR
- -396.04%
Profitability Metrics
| Metric | HALO | KYMR |
|---|---|---|
| ROE (TTM) | 216.38% | -27.29% |
| ROA (TTM) | 22.42% | -17.64% |
| Net Margin (TTM) | 26.93% | 0.00% |
| Operating Margin (TTM) | 59.84% | -396.04% |
| Gross Margin (TTM) | 77.74% | 0.00% |
Growth
Revenue Growth
Halozyme Therapeutics (HALO) at 37.55% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.
Growth Metrics
| Metric | HALO | KYMR |
|---|---|---|
| Revenue Growth (YoY) | 37.55% | -16.70% |
| Revenue Growth (3Y CAGR) | 28.38% | -5.74% |
| EPS Growth (YoY) | -25.36% | -- |
| EPS Growth (3Y CAGR) | 21.14% | -- |
Financial Strength
Current Ratio (MRQ)
Both Halozyme Therapeutics (HALO) at 3.88 and Kymera Therapeutics (KYMR) at 11.13 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.13
- Max
- 25.13
- Q3
- 12.13
- KYMR
- 11.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Kymera Therapeutics (KYMR) carries debt-to-equity ratio of 0.05 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.05
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- KYMR
- 0.05
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | HALO | KYMR |
|---|---|---|
| Current Ratio (MRQ) | 3.88 | 11.13 |
| Debt / Equity (MRQ) | -- | 0.05 |
| Net Debt / EBITDA | 1.90 | -- |
Dividends
Dividend Yield (TTM)
Neither Halozyme Therapeutics (HALO) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Halozyme Therapeutics (HALO) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | HALO | KYMR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Halozyme Therapeutics (HALO) trades at 25.91 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- KYMR
- --
P/S Ratio (TTM)
Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
110.00
- KYMR
- 110.00
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Kymera Therapeutics (KYMR) reports 6.96, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.96
- Max
- 13.53
- KYMR
- 6.96
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | HALO | KYMR |
|---|---|---|
| P/E Ratio (TTM) | 25.91 | -- |
| P/S Ratio (TTM) | 6.55 | 110.00 |
| P/B Ratio (MRQ) | -213.67 | 6.96 |
| Free Cash Flow Yield (TTM) | 3.48% | -1.46% |